PMID: 6161272Aug 15, 1980Paper

Problems of intravenous gammaglobulin therapy (author's transl)

Klinische Wochenschrift
J Ring, K H Duswald

Abstract

The presently available i.v. gammaglobulines (GG) can be classified into two groups. Degraded GG are produced by pepsin or plasmin digestion. Intact GG are obtained by beta-propiolactone treatment, acidification at pH or precipitation with polyethylenglycol-hydroxyethylstarch (PEG/HES). The various products have different characteristics with regard to their biological activity (certain functions of complement activation and opsonization are connected with the Fc structure) as well as their elimination (intact GG have longer intra- and extravasal half-life times). While their is no doubt about an effect of GG in animal experiments, little controlled studies have been done for most of the clinical indications. One controlled prospective study showed that in surgical high risk patients the frequency of septic complications can be reduced by prophylactic application of high doses of 7 S-GG. For the future, the development of a broad spectrum of hyperimmunoglobulines seems desirable.

References

Sep 30, 1978·British Medical Journal·J KoistinenJ Leikola
May 6, 1977·Deutsche medizinische Wochenschrift·R VollerthunH Ronneberger
Sep 25, 1978·Research in Experimental Medicine. Zeitschrift Für Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie·J RingW Brendel
Jan 1, 1976·International Archives of Allergy and Applied Immunology·J RingW Brendel
Jan 1, 1975·Vox Sanguinis·W Stephan
Aug 1, 1977·The Journal of Clinical Investigation·M A CatalanoJ H Vaughan
Apr 8, 1976·The New England Journal of Medicine·T W SmithV P Butler
Jan 1, 1975·Annual Review of Biochemistry·H J Müller-Eberhard
Oct 21, 1971·The New England Journal of Medicine·R KatzR Ward
Oct 21, 1971·The New England Journal of Medicine·J Stokes
Oct 28, 1966·Deutsche medizinische Wochenschrift·W CreutzfeldtU Tschaepe
Apr 25, 1968·The New England Journal of Medicine·C A JanewayJ D Crain
Aug 1, 1969·The Journal of Infectious Diseases·L S YoungJ V Bennett
Jan 1, 1974·Journal of Biological Standardization·V J Cabasso
Jan 1, 1974·Research in Experimental Medicine. Zeitschrift Für Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie·P S Tata, E Werner
Jan 1, 1974·Advances in Immunology·H L Spiegelberg
May 1, 1969·Proceedings of the National Academy of Sciences of the United States of America·G M EdelmanM J Waxdal
May 1, 1952·The Journal of Experimental Medicine·F J DIXONM DEICHMILLER
Oct 1, 1958·Proceedings of the Society for Experimental Biology and Medicine·W O WEIGLE, F J DIXON
Jan 1, 1962·Vox Sanguinis·S BARANDUNH ISLIKER
Aug 24, 1962·Deutsche medizinische Wochenschrift·H E SCHULTZE, G SCHWICK
Aug 1, 1963·The New England Journal of Medicine·E A KABAT
Mar 1, 1965·The Journal of Experimental Medicine·H L SPIEGELBERG, W O WEIGLE

❮ Previous
Next ❯

Citations

May 1, 1983·Pharmazie in unserer Zeit·J Ring

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Related Papers

Research in Experimental Medicine. Zeitschrift Für Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie
J RingW Brendel
European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery
T A PartanenJ Vuola
Revista Do Instituto De Medicina Tropical De São Paulo
R GuidolinH G Higashi
Journal of Cellular and Molecular Medicine
Maciej M MarkiewskiJohn D Lambris
© 2021 Meta ULC. All rights reserved